China to start online sales of prescription drugs; EMA approves 17 rare disease drugs in 2014; Legislation would allow Americans to buy cheaper Canadian drugs;

@FiercePharma: Catterton offloads PetVet hospital network to Canadian pension plan for $440M. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Court to give speedy answer in Actavis bid to yank old Namenda off market. Report | Follow @CarlyHFierce

> China is expected to begin online sales of prescription drugs as early as next month. Story

> The European Medicines Agency said that it approved 82 drugs in 2014 and that a record number, 17, are for rare diseases. Report

> India's Glenmark said in a filing that it does not intend to manufacture a copy of AbbVie's ($ABBV) Humira there, which competitor Zydus Cadilia is already making in India. Story

> Indian drugmakers say the government needs to beef up its regulatory infrastructure. Story

Medical Device News

@FierceMedDev: PureTech bumps its early life science funds up to $107M. Story | Follow @FierceMedDev

@EmilyWFierce: Adaptive Biotechnologies snatches up Sequenta to gain ground in cancer immunosequencing Story | Follow @EmilyWFierce

> In a win for Spectranetics, Covidien's to-be-divested drug-coated balloon earns CE mark. News

> C.R. Bard pushes for delay of vaginal mesh trial after judge's call for settlement. Article

Biotech News

@FierceBiotech: Incyte, Agenus partner on immuno-oncology targets in $410M deal. More | Follow @FierceBiotech

@JohnCFierce: Hey, UK readers. I'm moderating a panel Feb 4 at the Queen Mary Innovation Centre on #biotech finance. Invite only. More | Follow @JohnCFierce

@DamianFierce: Biogen signs a $30M deal with Columbia U. to sequence the genomes of "unusual" patients. Release | Follow @DamianFierce

> Orphazyme hauls in $24M to advance its rare disease contender. More

> Argos tanks as its HIV immunotherapy flunks Phase II. Story

> Euro VC Fountain unveils a $101M biotech fund. Item

And Finally... Senators John McCain (R-AZ) and Amy Klobuchar (D-MN) have again introduced legislation that would permit Americans to buy prescription drugs from Canada, where prices are lower because of price restrictions. Story

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.